Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tevimbra
Pharma
FDA limits Keytruda, Opdivo uses in stomach cancer
The two PD-1 inhibitors' FDA labels in gastric, gastroesophageal junction and esophageal cancers have been reduced to PD-L1-positive tumors only.
Angus Liu
Jun 9, 2025 10:50am
Akeso's fast-rising ivonescimab scores 3rd lung cancer trial win
Apr 23, 2025 11:30am
AstraZeneca-CSPC, Astellas and more—Fierce Pharma Asia
Oct 11, 2024 9:48am
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
Oct 4, 2024 10:37am
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
